Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2025-02-11 | "From 2020 to 2024, Ms. Urman served as Genomics Analyst at ARK Investments on ARK’s Genomic Revolution strategy, where she specialized in evaluating cutting-edge technologies... As a Senior Research Program Manager at IBM Watson Health, she championed the integration of AI in healthcare..." |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-25